substituted benzimidazolesfrom 1,1-dibromoethenes and o-diaminobenzenes is described. The reaction employs DABCO as the base and NMP as the solvent. A variety of substitutions on both 2-aryl-1,1-dibromoethenes and o-diaminobenzenes are tolerated. This new procedure is carried out under mildly basic conditions, which may provide a complementary route to the existing preparations of benzimidazoles.
Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction
作者:Zhen Wang、Min Zhang、Jin Wang、Haitao Ji
DOI:10.1021/acs.jmedchem.9b00147
日期:2019.4.11
64 and 0.44 μM, respectively, and exhibit good selectivity for β-catenin/Tcf over β-catenin/E-cadherin and β-catenin/adenomatous polyposis coli (APC) PPIs. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium (MTS) cell viability assays revealed that 56, the ethyl ester of 53, was more potent than 53 in inhibiting viability of most of the Wnt/β-catenin hyperactive
Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors
作者:Md Jawaid Akhtar、Anees Ahmad Siddiqui、Ahsan Ahmed Khan、Zulphikar Ali、Rikeshwer Prasad Dewangan、Santosh Pasha、M. Shahar Yar
DOI:10.1016/j.ejmech.2016.12.014
日期:2017.1
The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with anticancer and apoptotic activity were studied. Compounds 7a specifically inhibit EGFR and erbB2 receptor at 0.081 and 0.098 μM concentration. Some of the compounds showed strong, broad-spectrum antiproliferative activitiy when tested against five human cancer cell lines. Compounds